Clinical Trials Sponsored by Life Science Institute, Inc.

Total 629 results

Halucenex Life Sciences Inc.
KGK Science Inc.

Active, not recruiting

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

Post Traumatic Stress Disorder | Treatment Resistant Disorders

Canada
SK Life Science, Inc.
PRA Health Sciences

Completed

Bioavailability and Food Effect Study of 3 Types of Carisbamate

Healthy Subjects

United States
Nagoya University
Life Science Institute, Inc.

Completed

The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy (SHIELD)

Hypoxia-Ischemia, Brain

Japan
GeneOne Life Science, Inc.

Not yet recruiting

GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)

Healthy | Covid19

Puerto Rico
SK Life Science, Inc.

Recruiting

Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

Partial Epilepsy

Korea, Republic of, United States
GeneOne Life Science, Inc.

Not yet recruiting

GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery

Sinusitis Chronic

United States
SK Life Science, Inc.

Recruiting

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

Primary Generalized Epilepsy

United States, Spain, Germany, Hungary, Korea, Republic of, Australia, Bulgaria, Czechia, Poland, Slovakia, Ukraine
SK Life Science, Inc.

Enrolling by invitation

Cenobamate Open-Label Extension Study for YKP3089C025

Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy

United States, Bulgaria, Czechia, Hungary, Poland, Slovakia, Ukraine
SK Life Science, Inc.

Terminated

Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Advanced Solid Tumor

United States
SK Life Science, Inc.

Completed

Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment

Hepatic Impairment

Poland, Slovakia
SK Life Science, Inc.

Active, not recruiting

Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS

Partial Seizure | Focal Seizure

China, Japan, Korea, Republic of
SK Life Science, Inc.

Completed

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Serbia, Germany, Bulgaria, Argentina, Australia, Chile, Czechia, Hungary, Mexico, Poland, Russian Federation, Sweden, Thailand, Ukraine
SK Life Science, Inc.

Approved for marketing

Cenobamate Expanded Access Program (EAP)

Partial Epilepsy
SK Life Science, Inc.

Completed

A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users

Healthy Volunteer

United States, Canada
SK Life Science, Inc.

Completed

A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia

Schizophrenia

United States
SK Life Science, Inc.

Terminated

Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.

Epilepsy | Seizures
SK Life Science, Inc.

Completed

A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor

Essential Tremor, Movement Disorders
SK Life Science, Inc.

Completed

An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics

Diabetic Neuropathies
SK Life Science, Inc.

Terminated

Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures

Seizures
SK Life Science, Inc.

Completed

A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine

Migraine Headaches

United States
SK Life Science, Inc.

Completed

A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.

Epilepsy | Epilepsy, Complex Partial | Seizure Disorder | Complex Partial Seizures | Epilepsy, Focal
Bioenergy Life Science, Inc.

Completed

The Effect of Oral D-Ribose in "Baby Boomers" With Fatigue. A Randomized, Double-Blind Study

Fatigue

United States
GeneOne Life Science, Inc.

Active, not recruiting

GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)

SARS-CoV Infection | Pneumonitis

Korea, Republic of, Puerto Rico, United States, Bulgaria, North Macedonia
SK Life Science, Inc.

Completed

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

Australia, United States, Korea, Republic of, Germany, Hungary, Serbia, Bulgaria, Czechia, France, Israel, Poland, Romania, Spain, Thailand, Ukraine
SK Life Science, Inc.

Completed

Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet

Healthy

United States
SK Life Science, Inc.

Completed

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy

Painful Diabetic Neuropathy

United States
SK Life Science, Inc.

Completed

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States
SK Life Science, Inc.

Completed

An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.

Epilepsy | Epilepsies, Partial | Epilepsy, Complex Partial | Complex Partial Seizures
SK Life Science, Inc.

Completed

An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures

Epilepsy, Complex Partial | Epilepsy, Partial, Motor | Epilepsy, Simple Partial | Focal Motor Epilepsy
SK Life Science, Inc.

Completed

A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.

Epilepsy, Complex Partial | Epilepsy, Partial, Motor | Epilepsy, Simple Partial | Focal Motor Epilepsy
SK Life Science, Inc.

Completed

An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy

Epilepsy | Epilepsies, Partial
SK Life Science, Inc.

Completed

A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.

Epilepsy | Epilepsy, Complex Partial | Seizure Disorder | Complex Partial Seizures | Epilepsy, Focal
SK Life Science, Inc.

Recruiting

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Seizures | Lennox Gastaut Syndrome

United States, Korea, Republic of, Taiwan, Colombia, Israel, Poland, Serbia, Mexico, Argentina, Spain, Greece, Italy, Portugal, Germany
SK Life Science, Inc.

Recruiting

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Germany, Australia, Poland, Hungary
SK Life Science, Inc.

Completed

Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

Lennox Gastaut Syndrome

United States
GeneOne Life Science, Inc.

Active, not recruiting

GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)

COVID-19 | Healthy

Puerto Rico, United States
SK Life Science, Inc.

Completed

Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome

Lennox Gastaut Syndrome

United States
SK Life Science, Inc.

Completed

A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 mg Cenobamate Administered Orally

Healthy Volunteers

United States
GeneOne Life Science, Inc.

Terminated

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

SARS-CoV 2 | Infection

United States
GeneOne Life Science, Inc.

Active, not recruiting

GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)

SARS-CoV-2

Korea, Republic of
SK Life Science, Inc.

Completed

Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

Partial Epilepsy

Korea, Republic of, United States, India, Poland
SK Life Science, Inc.

Completed

An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).

Neuralgia | Herpes Zoster | Postherpetic Neuralgia
SK Life Science, Inc.

Completed

Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).

Diabetic Neuropathy, Painful | Diabetic Polyneuropathy | Diabetic Neuralgia | Diabetic Mononeuropathy
SK Life Science, Inc.

Completed

Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs as a Means of Predicting Drug-drug Interactions

Healthy

United States
SK Life Science, Inc.

Completed

A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation

Chronic Constipation | Functional Constipation

United States
SK Life Science, Inc.

Completed

An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy

Epilepsy | Epilepsies, Partial
SK Life Science, Inc.

Completed

Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures

Seizures
SK Life Science, Inc.

Completed

Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy

Refractory Epilepsy

United States, Poland, United Kingdom, Spain, Netherlands, Russian Federation, Hungary, Argentina
Bioenergy Life Science, Inc.

Suspended

The Role of Ribose in Patients Diagnosed With Fibromyalgia

Fibromyalgia

United States
ReAlta Life Sciences, Inc.

Not yet recruiting

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease (AURORA)

Steroid Refractory GVHD

3

Subscribe